

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2019 ANNUAL REPORT

Reference is made to the annual report of Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”, together with its subsidiaries) for the year ended 31 December 2019 published on 22 April 2020 (the “2019 Annual Report”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2019 Annual Report.

In addition to the information provided in the 2019 Annual Report, the Company would like to provide shareholders of the Company and the public with further information in relation to the other expenses for the year ended 31 December 2019 as below (together with comparative figures for 2018).

Other expenses for the years included:

	For the year ended 31 December	
	2019	2018
	RMB'000	RMB'000
Loss on disposal of items of property, plant and equipment	656	346
Impairment of intangible assets	6,438	1,697
Amortisation on capitalised research and development costs	1,762	418
Donations	32	658
Write-down of inventories to net realisable value	10,142	4,383
Written off of obsolete stocks	2,974	1,802
Impairment of property, plant and equipment	102	-
Current year expenditure of research and development costs	47,889	45,934
Foreign exchange loss	-	182
Others	814	4,516
	<u>70,809</u>	<u>59,936</u>

**for identification purpose only*

The supplemental information provided in this announcement does not affect other information contained in the 2019 Annual Report and, apart from the information disclosed in this announcement, the remaining contents of the 2019 Annual Report remain unchanged.

By Order of the Board of
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 20 August 2020

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.